COVID-19 Research and Development: Four Major Pharmaceutical Companies Announced The Latest Today

The outbreak of the new coronal has been going on for months, and as research into the new coronavirus and COVID-19 deepens, people recognize not only its complexity, but also the fact that it is not a cure, or a vaccine, that can solve the global pandemicToday, the latest initiatives of several large biopharmaceutical companies also reflect the biopharmaceutical community's efforts to explore more COVID-19 prevention and treatment methods in a number of waystoday, Roche's Genentech announced today that it will work with Gilead Sciences to launch a randomized double-blind, global Phase 3 clinical trial to test its IL-6 monoclonal antibody Actemra (tocilizumab), which is linked to the antiviral drug Redcivir, to treat the safety and efficacy of patients hospitalized with severe new coronary pneumoniaAs the study of COVID-19 progressed, scientists realized that the cause of exacerbation of the condition in patients with neo-coronary pneumonia was not only damage to tissues caused by viral infections, but also inflammatory damage caused by the body's excessive immune responseRecently, Redsyway was validated in Phase 3 clinical trials to improve recovery in patients with severe new coronary pneumoniaSo, can this antiviral therapy and the drug that suppresses the inflammatory response lead to better treatment?Genentech has launched a Phase 3 clinical trial to test the safety and efficacy of Actemra's treatment of patients hospitalized with severe new coronary pneumoniaIL-6 plays a key role in cytokine storms in patients with co-mediated neo-coronary pneumoniaActemra is an anti-IL-6 monoclonal antibody that has been approved to treat rheumatoid arthritisGenentech said phase 3 clinical trials to test Actemra's monodotherapy have been registered and are expected to be available this summerPhase 3 clinical trial of the test combination therapy is expected to enroll 450 patients and will begin to register patients in Junebased on the same scenario, the U.SNational Institute of Allergy and Infectious Diseases (NIAID) has also launched clinical trials to study the safety and efficacy of patients with severe neoprene pneumonia, a combination of redsiewe and JAK inhibitor OluminantToday, the University of Pennsylvania announced that the Department of Gene Therapy, led by renowned gene therapy pioneer Professor James Wilson, will join a vaccine development project led by researchers at Massachusetts Eye and Ear Hospital and Massachusetts General HospitalThe vaccine development project, called AAVCOVID, aims to develop adeno-related virus (AAV) vectors that express the new coronavirus gene as a vaccine against neo-coronavirus infectionAAV is a commonly used viral vector in a variety of gene therapies, and Professor Wilson has deep experience in developing and optimizing AAV vectorsDrLuk Vandenberghe, the lead author of the AAVCOVID program, was a Doctoral Student in Professor Wilson's LaboratoryWhile studying in Professor Wilson's lab, he designed an AAV vector that stimulates the body's immune responseThe expression of the new coronavirus gene with this AAV vector is expected to stimulate a strong human immune responseAt the same time, the safety of AAV vectors has been validated in clinical trials of several gene therapiesat the same time, AveXis, a gene therapy company owned by Novartis, announced its participation in the vaccine developmentNovartis' approved gene therapy For Spinal Muscular Dystrophy (SMA), Zolgensma, was developed and produced by AveXisThis is a gene therapy based on aAV vectorAveXis announced that it will use its expertise and production capacity in gene therapy to produce the candidate vaccine free of charge to support clinical trials to be conducted later this year"The first question that often needs to be answered for new crown vaccine development projects is - how can this vaccine expand production?" Dr Vandenberghe said: "AveXis has mass-produced Gene therapy products based on AAV vectorsWorking with the company will help us reach our goal of sending vaccines globally to prevent new coronavirus infections"
GlaxoSmithKline (GSK) today announced plans to produce 1 billion doses of pandemic vaccine adjovant (adjuvant) system by 2021 to support the development of a number of new coronavirus candidate vaccines using adjoditeGSK believes that its adjuno technology can make a significant contribution to the capture of COVID-19The adjuas reduce the amount of viral protein in each dose of the vaccine, thus producing more doses of the vaccine and protecting more peopleMoreover, adjfrom the body's immune response can help stimulate a stronger and longer-lasting immune responseGSK has entered into research and development agreements with Sanofi, the University of Queensland and Shamrock Biopharma to provide adjother to support the development of the new crown vaccine for these institutions "We believe that we need more than one vaccine to overcome this global pandemic," said Roger Connor, global president of GSK That's why we work with our global partners to support efforts to combat COVID-19 "
(original title: COVID-19 Research and Development: What are the new initiatives of Roche, Gilead Science, Novartis, GlaxoSmithKline)?